They share one receptor and disagree about the second.
If you are weighing these two, you already know the shape of the market. Tirzepatide is the one you can get, the one with the largest trials and the highest headline number. Mazdutide is the one arriving behind it, approved in China first, with a different second mechanism and a story that sounds a lot like tirzepatide's did three years ago.
This mazdutide vs tirzepatide comparison puts the two side by side on the things that decide the choice: what each targets, what the trials actually measured, how the numbers compare when you account for trial length, and which one you can realistically use this year.
🔑 Key Takeaways
- Both are dual agonists built on GLP-1. Tirzepatide's second target is GIP; mazdutide's is glucagon. That single difference drives everything else on this page.
- The headline numbers are not comparable as printed. One comes from a 72-week trial at 15 mg, the other from a 32-week trial capped at 6 mg. Read side by side they flatter tirzepatide more than the biology justifies.
- Glucagon agonism does something GIP does not, and it matters for one specific group of people more than for the scale.
- Access is the deciding factor for almost everyone in 2026, and it is not close.
- There is one situation where waiting for mazdutide is a defensible choice, and it is narrower than the hype suggests.
Tirzepatide's other rivals each have their own page: retatrutide, which adds both GIP and glucagon, and survodutide, which shares mazdutide's glucagon mechanism. This page is only about mazdutide.
What each drug actually targets
Same first receptor, different second one.
Tirzepatide activates GLP-1 and GIP receptors. GLP-1 does the appetite and gastric-emptying work you feel. GIP is the quieter partner: it appears to improve how fat tissue handles energy and to blunt some of the nausea GLP-1 alone causes, which is one reason tirzepatide's side-effect profile is often described as gentler than semaglutide's at equivalent loss.
Mazdutide activates GLP-1 and glucagon receptors. Glucagon is the interesting choice, because on its own it raises blood sugar, which is the last thing you want in a metabolic drug. Paired with GLP-1 that effect is held in check, and what remains is glucagon's other job: increasing energy expenditure and driving fat oxidation, particularly in the liver.
The practical translation is that tirzepatide works mostly by reducing what goes in. Mazdutide works by reducing what goes in and raising what gets burned, with a specific pull toward liver fat. Whether that second lever produces more total weight loss is exactly what the trials have not yet settled head to head.
Mazdutide vs tirzepatide: the trial numbers, honestly framed
The gap looks bigger than it is.
Three things make a straight comparison of 20.9% and 12.6% misleading. The tirzepatide figure is at 72 weeks and the mazdutide figure at 32, and weight loss on these drugs is still climbing at 32 weeks. The tirzepatide top dose is 15 mg; mazdutide's trial capped at 6 mg, with higher doses now being studied. And the trial populations differ in starting weight, which changes percentages. At matched time points the gap narrows considerably. Whether it closes is not yet known.
Where the glucagon mechanism actually matters
The liver, mostly.
Glucagon receptor activation increases fat oxidation in the liver directly, rather than only through weight loss. The mazdutide trials have shown large reductions in liver fat, and that is the finding that separates it from a GLP-1/GIP drug rather than the scale number. For someone whose main concern is fatty liver disease, that is a real difference in kind, not degree.
There is a cost to it. Glucagon raises heart rate and, in some people, blood pressure, and it can nudge blood sugar up in ways that GLP-1 has to offset. Tirzepatide's GIP partner does the opposite, which is part of why tirzepatide tends to be easy on cardiovascular measures. Whether mazdutide's profile holds up in longer trials is one of the open questions.
Side effects: same family, different emphasis
Both are gut drugs first.
Nausea, vomiting, diarrhoea and constipation lead the list for both, concentrated in the weeks after each dose increase and easing with time. That part is shared across the whole class. What differs is around the edges. Tirzepatide's GIP component is thought to blunt nausea somewhat, and in its trials discontinuation for side effects ran in the mid single digits. Mazdutide's glucagon component brings the heart-rate question, and its shorter trials leave less long-term safety data to lean on.
For most people the honest summary is that the day-to-day experience will feel similar, and the meaningful differences are the ones a doctor watches on a monitor rather than the ones you feel. Tirzepatide's full profile is in our side effects guide.
Which one can you actually use?
In 2026, this decides it.
Tirzepatide is approved in the US and most major markets as Mounjaro and Zepbound, available through insurance, LillyDirect self-pay, telehealth and, with narrower legal footing than before, compounding. The routes and what each costs are laid out in compounded tirzepatide.
Mazdutide is approved in China for weight management and has no FDA approval. Outside China it exists only as a laboratory-labelled peptide from vendors, with all the sourcing and verification problems that route carries and none of the prescriber oversight. Our mazdutide guide covers what is known about dosing and what is not.
That asymmetry is the practical answer for most readers. A drug with 72 weeks of trial data and a prescription route beats a drug with 32 weeks and a grey one, unless the second drug's specific mechanism is the reason you are looking.
The one case for waiting on mazdutide
Diagnosed fatty liver disease is the scenario where mazdutide's glucagon action is a genuine, mechanism-level advantage rather than a marketing point. If that is your primary concern and you are not in a hurry, following its US regulatory path is reasonable.
For weight loss alone, tirzepatide is the higher-evidence, higher-access, higher-number choice right now, and nothing in mazdutide's current data overturns that.
Frequently Asked Questions
Medical disclaimer. This article is informational and does not replace individual medical advice. Tirzepatide is a prescription medicine and mazdutide has no US approval; neither should be started, switched or stopped without a clinician. The trial figures above are population averages from studies of different lengths, doses and populations, and are presented to show scale rather than to predict an individual outcome. Anyone with a history of pancreatitis, thyroid cancer, gallbladder disease or cardiovascular disease, or who is pregnant or planning pregnancy, should discuss any GLP-1 based treatment with a doctor before starting.